Recursion Pharmaceuticals (UT, USA) has announced that it will receive 12.9 million in funding for development of its next generation drug discovery platform that combines high-throughput biology and automation with the newest advances in artificial intelligence (AI). So far, the company has successfully repurposed known drugs, bioactive compounds, and shelved pharma assets in the space of rare genetic disease. With its Series A funding, Recursion hopes to scale up its venture from the exploration of dozens of targets and diseases per year to thousands. Recursion intends to continue focusing on drug repurposing and repositioning, an attractive strategy for big pharma since it leverages existing safety and efficacy data to translate discoveries into the clinic more rapidly and more economically. The company will be primarily partnering with deep technology investor Lux Capital (CA, USA), with participation from Obvious Ventures (CA, USA), Epic Ventures (UT, USA), Data Collective (CA, USA), AME Cloud Ventures (CA, USA), and several angel investors.